ENCANTO
ENCANTO introduces an innovative regenerative treatment for patellofemoral (knee-cap) osteoarthritis (PFOA) based on biological cartilage grafts engineered from nasal cartilage cells (chondrocytes), named N-TEC (Nasal chondrocyte Tissue Engineered Cartilage).
ENCANTO (ENgineered CArtilage from Nose for the Treatment of Osteoarthritis) is an international multicenter randomized clinical phase II study on knee-cap osteoarthritis.
This therapy is expected to regenerate the cartilage tissue, sustainably restore joint homeostasis, reduce pain, improve mobility and thereby enable an active life for young and elderly patients.
The study is funded by the European Union within the frame of the Horizon Europe project: HORIZON-HLTH-2023-TOOL-05-01 under grant agreement No.101137315.
Project duration is from Januray 1 st 2024 till December 31 th 2029.
Project is co-funded by EU 9 th Framework Programme within Horizon Europe with 8,363,555.00 € and by The State Secretariat for Education, Research and Innovation (SERI) from Switzerland with 3,452,277.5 €.
Project coordinator is prof. Gianluca Vadalà from Campus Bio-Medico University of Rome, Italy.
(Universität Basel, photo by Christian Flierl)
The study will be carried out in 11 clinical centers:
- Universitätsspital Basel (Basel, Switzerland)
- Crossklinik Basel (Basel, Switzerland)
- Fondazione Policlinico Universitario Campus Bio-Medico (Rome, Italy)
- Ospedale Galeazzi Spa (Milan,Italy)
- König-Ludwig-Haus University of Würzburg (Würzburg, Germany)
- Evangelisches Waldkrankenhaus Spandau (Berlin, Germany)
- Klinička Bolnica Sveti Duh (Zagreb, Croatia)
- Orthopädisches Spital Speising GMH (Vienna, Austria)
- Oddzial Chirurgii Oroptedyczno-Urazowej Szpital Specjalistyczny im Stefana Zeromskiego (Krakow, Poland)
- Goeteborgs Universitet (Gothenburg, Sweden)
- Maastricht University Medical Centre+ (Maastricht, Netherlands)